Min Fang, MD, PhD

Clinical and Research Background

Dr. Fang received her medical training at the prestigious Shanghai Medical University in China, specializing in Clinical Pathology/Laboratory Medicine. After working as a Clinical Geneticist for two years, Dr. Fang pursued a Ph.D. degree in Cellular and Molecular Biology at the University of Alabama at Birmingham, followed by fellowship training in Clinical Molecular Genetics and Clinical Cytogenetics at the Stanford University, California. She has served as a genetics lab director for twelve years and is board-certified in both Clinical Molecular Genetics and Clinical Cytogenetics by the American Board of Medical Genetics.

Dr. Fang’s current clinical service is as Director of the Cytogenetics Department at the Seattle Cancer Care Alliance, responsible for the clinical operation and daily sign-out of cytogenetic/molecular testing on adult and pediatric patients undergoing hematopoietic stem cell transplantation as well as other cancer patients. She was Director of Human Molecular Genetics laboratory and Section Chief for Oncology Cytogenetic Testing while at the University of Connecticut Health Center. She served on the Genetics Review Panel of Center for Disease Control, Nominating Committee of the Association for Molecular Pathology, Lea’s Foundation Hematology Advisory Committee, University of Connecticut Translational Genomics Core Advisory Committee, and is currently the Cytogenetics Subcommittee co-Chair of SWOG Leukemia Committee since 2009 and the Chair-Elect of the Publication and Communication Committee of the Association for Molecular Pathology (AMP).

The focus of Dr. Fang’s laboratory research is on the genomics and combinatorial genetics/epigenetics of human neoplasia. Combining classical genetic approaches of mapping, karyotyping, fluorescence in situ hybridization, single-gene mutation analysis, bisulfite sequencing, and functional genetics with new genomic tools including microarray, comparative genome hybridization, and next-generation sequencing, we aim to identify genetic and epigenetic aberrations in cancer that are prognostically significant and may serve as actionable biomarkers for treatment decision making for individual patients. Dr. Fang’s research is currently supported by funding from the National Institute of Health and the HOPE Foundation.

Dr. Fang is also dedicated to and enthusiastically promotes medical teaching in training the best physicians, researchers and health care professionals for the current and next generation. Dr. Fang served as the coordinator/lead of the Human Genetics section of the medical/dental school education and served on the Medical School Admissions Committee of the University of Connecticut Health Center. She is currently involved in post-graduate medical training of fellows, residents and postdoctoral research fellows at the Fred Hutchinson Cancer Research Center and University of Washington.